115 filings
Page 6 of 6
8-K
p9x905j3juhmw
5 Nov 18
First-in-human Phase 1b / 2 combination trial of BXCL701 and pembrolizumab (Keytruda®) expected to initiate in 4Q 2018
4:30pm
8-K
v6aw 9wslmhsc
30 Oct 18
BioXcel Therapeutics Provides Update on the Clinical Advancement of BXCL501 for the Acute Treatment of Agitation
8:15am
8-K
qe3ea9o72b8ok69py
26 Sep 18
BioXcel Therapeutics Expands Immuno-Oncology Partnership with Nektar into Clinical Development in Pancreatic Cancer
12:00am
8-K
kjnz36luz4awgdfxps
23 Aug 18
Entry into a Material Definitive Agreement
12:00am
8-K
unwl241synffv7gnck
8 Aug 18
BioXcel Therapeutics Reports Second Quarter 2018 Financial Results and Provides Business Update
4:02pm
8-K
3hkgpa
24 Jul 18
DPP8/9 Inhibition - The Primary Mechanism of BioXcel Therapeutics’ Lead Immuno-Oncology Asset, BXCL701, Highlighted in Peer-Reviewed Journal
5:20pm
8-K
hvprosrxr3i0
27 Jun 18
BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine Supporting BXCL501 Development
4:17pm
8-K
wbxqh64v
7 Jun 18
Regulation FD Disclosure
5:10pm
8-K
rjt8f i08b
7 Jun 18
BioXcel Therapeutics Appoints Vincent J. O’Neill M.D., as Senior Vice President and Chief Medical Officer
4:01pm
8-K
rw2zhm6
4 Jun 18
Results Support Further Development of triplet therapy
12:00am
8-K
6r4e59hlnprm2
21 May 18
Regulation FD Disclosure
4:21pm
8-K
y5nyaweeoaju0
17 May 18
BioXcel Therapeutics Announces Data Presentation at ASCO 2018 Annual Meeting
4:17pm
8-K
rj53x1b rmy
14 May 18
BioXcel Therapeutics Reports First Quarter 2018 Financial Results and Provides Business Update
4:19pm
8-K
7t0w4qnh7twbotwz f4v
26 Apr 18
BioXcel Therapeutics Announces Acceptance of Abstract at ASCO 2018 Annual Meeting
4:12pm
8-K
pr7e7bols5ul sdh
13 Mar 18
BioXcel Therapeutics Announces Pricing of Initial Public Offering
12:00am